Clinical Trial · NCT06370234

The Prediction Model of NAC Response for Breast Cancer Based on The Parametric Dynamics Features.

Overview

The main purpose of this study is to develop a computer-aided prediction model for NAC treatment response. Based on the heterogeneity of internal parametric tumor composition commonly observed, this study will utilize the histologic characteristics and treatment response to investigate the image features as input data for predicting treatment response using Deep Learning technology. Using this technique, preoperative treatment evaluation may be facilitated by tumor heterogeneity analysis from developed dynamic radiomics, and the possibility of personal medicine can be realized not far ahead. In the first two years of this study using images from DCE-MRI, PET/CT and QDS-IR, we plan to develop the image processing algorithms, including segmenting breast and tumor region, extracting image feature which reflects angiogenic properties and permeability of tumor, which are highly correlated with NAC treatment response. During the third year of the project, the morphology and texture features from first two years can be combined for PET/MRI and prediction model can be achieved in accordance with the features extracted from dynamic features extraction using longitudinal images of PET/MRI.

Sponsor

National Taiwan University Hospital

Phase

N/A

Contacts

Yeun-Chung Chang, M.D., PhD. (STUDY_CHAIR)

ClinicalTrials.gov

NCT06370234

Drug / Compound

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

Eligibility

Inclusion

  • (d) were eligible for surgery after NAC
  • (e) were willing to undergo at least three PET/MR scans during NAC: the first \[R0\], pre-treatment; and the second \[R1\], after two cycles of chemotherapy (post-treatment) and before surgery \[R2\]
  • (c) were willing to undergo NAC
  • (b) with pathologically confirmed breast cancer with core needle biopsy

Exclusion

  • (c) Impaired renal function, CCR\>30ml/min.
  • (a) distant metastases or recurrent breast cancer.
  • (b) unable to comply with sequential PET/MR scanning schedule.